Sergio Cifuentes Canaval: KN 189 and 407 – Pooled Analysis of Outcomes
Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared on LinkedIn:
“KN 189 and 407: Pooled Analysis of Outcomes After 5 Years of Follow-Up of Pembrolizumab + CHT for mNSCLC with PDL1 < 1%:
There is an urgent need in NSCLC treatment with PD-1 inhibitor less than < 1% without drivers mutations, Pembrolizumab has shown efficacy in combination with chemotherapy in this population.
Methods:
In this pooled analysis, data from four phase 3 studies were included: KEYNOTE-189, KEYNOTE-407, the Japanese extension of KEYNOTE-189, and the Chinese extension of KEYNOTE-407. Patients with metastatic NSCLC without EGFR or ALK alterations received pembrolizumab or placebo along with different chemotherapy regimens. PD-L1 expression was assessed using immunohistochemistry (IHC).
Results:
OS: Pembro + CHT: improved OS, HR 0.64.
PFS: HR 0.66 for the combination of Pembro + CHT.
5-Year OS Rates: 12.5% (pembrolizumab + chemotherapy) vs. 9.3% (CHT alone).
Conclusion:
With 5 years of follow-up, pembrolizumab + chemotherapy continues to demonstrate significant and durable survival improvements in patients with metastatic NSCLC and PD-L1 TPS <1%, with a significant reduction of the risk of death or progression in 35% aprox.”
Visit the article website.
Source: Sergio Cifuentes Canaval/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023